علاج نقص بروتين S في أعقاب الجلطة الوريدية الانسدادية الحادة

References

DOI: 10.1186/s12959-026-00861-w

• Nineteen patients, who had an acute clinical event (VTE) right before or during the observation at the Center, underwent treatment with Enoxaparin (range 4000–16000 IU/die) or Fondaparinux (range 2.5–7.5 mg/die) according to the clinical conditions, after ruling out high-risk antiphospholipid syndrome.
• The duration of this therapy was 3 to 6 months because other professionals had prescribed it.
• Subsequently, the majority of these patients underwent a full-dose of doac therapy (apixaban 5 mg BID or rivaroxaban 20 mg once a day).
• The time spent in full dose was of 12 months, on average.
• At 3 and 6 months, when deep vein recanalization occurred or embolism symptoms/signs improved or disappeared, apixaban was reduced from 5 to 2.5 mg BID and rivaroxaban from 20 to 10 mg/once a day, monitoring compliance with plasma levels of doac.